一个新的糖尿病肢体保护计划
1*Clinical Professor, Podiatric Surgery, Department of Diabetes, Endocrinology and Metabolism Department of Oncologic Surgery, City of Hope National Comprehensive Cancer Center Duarte, CA. Diplomate, American Board of Foot and Ankle Surgery; Diplomate, American Board of Podiatric Medicine.
Journal of the American Podiatric Medical Association
|August 21, 2025
概括
在糖尿病患者中,将糖尿病脚症状的患者教育与足部护理相结合,显著减少了糖尿病脚和截肢. 这种方法可以提高患者的参与度和早期发现并发症.
科学领域:
- 癌症学
- 内分泌学
- 足部医学
背景情况:
- 糖尿病足和截肢是糖尿病患者发病率和死亡率的重要原因.
- 患有糖尿病的癌症患者因免疫抑制,神经病变和血管问题而面临更大的风险.
- 这种患者的脚部并发症可能导致癌症治疗暂停,造成危及生命的风险.
研究的目的:
- 评估将以症状为重点的患者教育与协调的足部护理相结合的影响.
- 为了减少糖尿病癌症患者的DFU和下肢截肢的发生率.
- 评估新肢体保护倡议模式的有效性.
主要方法:
- 在NCI指定的癌症中心进行了五年后期的评估.
- 包括正在接受各种癌症治疗的II型糖尿病患者.
- 基于自我报告的症状和个性化足部护理的有针对性的教育模块,包括例行检查和监测.
主要成果:
- 达到了2.8%的DFU发生率和0.43%的截肢率,低于国家基准.
- 通过以症状为重点的教育来提高患者参与度.
- 有助于更早地发现脚部并发症,包括看似微不足道的问题.
结论:
- 将糖尿病脚症状教育与主动足部监测相结合,可显著减少足部损伤和截肢.
- 新肢体保护倡议模式是针对高风险群体的可扩展战略.
- 这种模式有望在多样化,缺乏服务的社区中得到更广泛的实施.
相关概念视频
Peripheral Artery Disease III: Interprofessional Care
29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29
Peripheral Artery Disease IV: Nursing Management
43
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
43
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
34
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
34
Peripheral Artery Disease V: Postoperative Nursing Management
25
During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
25
Peripheral Artery Disease I: Introduction
32
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
32
Dipeptidyl Peptidase 4 Inhibitors
256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256


